Hengrui Pharma and Kailera Therapeutics Present Ribupatide Clinical Data at ADA 2026

About this update from Kailera Therapeutics, Inc.

Presentations will feature clinical results for ribupatide, a GLP-1/GIP receptor dual agonist being developed as a once-weekly injection and a once-daily oral pill for the treatment of obesity and overweightAdditional data from Phase 2 obesity clinical trial of ribupatide oral demonstrating mean weight loss of up to 12.1% with no observed plateau and up to 38.6% of participants achieving at least 15% weight loss at 26 weeks; incidence of gastrointestinal adverse events was low, with vomiting reported in 11.4% and 7.5% of participants taking 25 mg and 50 mg ribupatide oral, respectivelyPhase 1 single ascending dose trial, the first ribupatide injection clinical data generated outside of China, demonstrated similar exposure, tolerability, and weight reduction in participants of Asian and non-Asian descent SHANGHAI and WALTHAM, Mass., June 05, 2026 (GLOBE NEWSWIRE) -- Hengrui Pharma (Hengrui), a global pharmaceutical company focused on scientific and technological innovation, and Kailera Therapeutics, Inc. (Kailera), a clinical-stage biotechnology company focused on elevating the next era of obesity care, today announced clinical results for ribupatide (also known as HRS9531 or KAI-9531), a GLP-1/GIP receptor dual agonist being developed as a once-weekly injection and a once-daily oral pill for the treatment of obesity and overweight, presented at the 86th Scientific Sessions of the American Diabetes Association (ADA). “Building on our previously reported topline data, we are pleased to share additional results from our Phase 2 clinical trial of ribupatide oral in China. These findings further support its potential as a differentiated oral treatment option for people living with overweight or obesity,” said Su Zhang, Vice President and Head of Non-Oncology Clinical Development, Hengrui Pharma. “We are focused on rapidly advancing into Phase 3 in China this year with the goal of delivering this potential new option to patients. We also recognize the Kailera team for presenting the first ribupatide injection data generated outside of China, marking a meaningful step in establishing its role in the global obesity treatment landscape.” “It is exciting to see clinical results for both ribupatide injection and ribupatide oral at ADA this year — highlighting the potential of ribupatide to deliver differentiated options for people living with obesity and overweight....

View stock analysis, news, and events for Kailera Therapeutics, Inc.